Huzhou Saihan Equity Investment Partnership Enterprise (Limited Partnership) completed the acquisition of 5% stake in Heilongjiang ZBD Pharmaceutical Co., Ltd. from Hulin Longpeng Investment Center.
June 09, 2022
Share
Huzhou Saihan Equity Investment Partnership Enterprise (Limited Partnership) signed a share transfer agreement to acquire a 5% stake in Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) from Hulin Longpeng Investment Center for approximately CNY 640 million on April 15, 2022. As part of the transaction, Huzhou Saihan Equity Investment Partnership will acquire 47,098,180 shares for CNY 13.56 per share. In related transaction, Huzhou Saihan Equity Investment Partnership Enterprise (Limited Partnership) signed creditor's rights Transfer Agreement with Hulin Longpeng Investment Center, and the consideration for the transfer of the underlying shares shall be deemed to have been paid as of the date when the creditor's rights Transfer Agreement and the Share Transfer Agreement are signed and come into effect.
Huzhou Saihan Equity Investment Partnership Enterprise (Limited Partnership) completed the acquisition of 5% stake in Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) from Hulin Longpeng Investment Center on June 10, 2022.
HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.